BioSpace News Archive

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801) announced the preliminary data of IBI351 (GFH925, KRASG12C inhibitor) is presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

Telix Pharmaceuticals Limited advises that Dr Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the Jefferies Healthcare Conference being held in New York from June 7 to June 9, 2023.

Biophytis SA announces it will participate at the Biotechnology Innovation Organization International Convention to be held in Boston from the 5th to the 8th of June 2023, alongside thousands of world leaders in biotechnology and the pharmaceutical industry.

Gencurix, a leading provider of cancer molecular diagnostics, announced the release of clinical research results directly comparing the accuracy of its breast cancer prognostic test, GenesWell BCT, with Oncotype DX, the globally top-selling test, confirming its outstanding performance.

Evotec SE presents an update on the Company’s sustainability strategy and shares details on its ESG performance towards strengthening its competitiveness and contributing to a better future for next generations to investors and interested stakeholders at its virtual Capital Markets Day.

VaxEquity, developing transformative RNA vaccines and therapeutics based on its next generation self-amplifying RNA platform, and CPI, the UK’s leading independent technology innovation centre, announce a grant of approximately £700K from Innovate UK.

ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, announced an equity investment round of €255 million led by Temasek with participation from BlackRock Alternatives1,Qatar Investment Authority, Nextech2, ATHOS and Carbyne.

CatalYm announced first Phase 2a data from its ongoing GDFather-2 trial at the American Society of Clinical Oncology Annual Meeting 2023 in Chicago, Illinois.

Sirnaomics Ltd., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced the interim results of an ongoing Phase I clinical trial of STP705, an siRNA drug candidate, for fat reduction in adults undergoing abdominoplasty.

KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted three newly-hired employees inducement options to purchase an aggregate of 40,000 shares of KalVista common stock on June 1, 2023 as inducements material to each employee entering into employment with KalVista.